A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women.
Cancer Clinical Trials
Advanced ER+/AR+ Breast Cancer
Androgen Receptor-Positive Triple Negative Breast Cancer
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+TNBC).
Breast - Metastatic, BRCA 1 and BRCA 2
Brocade 3 (M12-914)
A Phase 3 randomized placebo-controlled trial of carboplatin and paclitaxel with or without veliparib (ABT-888) in HER2-negative metastatirc or locally advanced unresectable BRCA-associated breast cancer.
ASBrS Nipple Sparing Mastectomy Registry.
Breast – Early stage
A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy with Abemaciclib in Combination with Anastrozole in Postmenopausal Women with Hormone Receptor Positive, HER2 Negative Breast Cancer.
Colorectal Cancer – Treatment experienced
A Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer.
Gastric – Metastatic
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin with or without Ramucirumab as First-line Therapy in Patients with Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.
City of Hope Registry
Molecular Genetics Studies of Cancer Patients and Their Relatives
Lung – Early Stage
A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (ANTI−PD-L1 Antibody) Compared with best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in PD-L1−Selected Patients with Completely Resected Stage Ib−IIIa Non−Small Cell Lung Cancer.
Lung – Metastatic
A Phase III, Open-label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti−PD-L1 Antibody) in Combination with Carboplatin+Paclitaxel or Atezolizumab in Combination with Carboplatin+Nab-Paclitaxel versus Carboplatin+Nab-Paclitaxel in Chemotherapy-naive Patients with Stage IV Squamous Non−small Cell Lung Cancer.
Lung – Metastatic
A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti−Pd-L1 Antibody) in Combination with Carboplatin + Paclitaxel with or without Bevacizumab Compared with Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non−Small Cell Lung Cancer.
Keynote-252 / ECHO-301
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma.
A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy.
Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukemia (AML)
Connect® MDS and AML Registry
Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.